Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063507 | 1.00 | HSD17B10 (0.42) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL16749946 | 1.00 | HSD17B10 (0.42) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL1041478 | 1.00 | HSD17B10 (0.42) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL12004645 | 1.00 | HSD17B10 (0.42) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL25728044 | 0.96 | HSD17B10 (0.40) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL25728385 | 0.94 | HSD17B10 (0.37) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL12022441 | 0.93 | HSD17B10 (0.38) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL16749993 | 0.93 | HSD17B10 (0.38) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL10016097 | 0.93 | HSD17B10 (0.38) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 | |
| SCHEMBL14585810 | 0.93 | HSD17B10 (0.38) | HSD17B10PLA2G10PLA2G5CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619924-A | PROTAC compound for targeted degradation of CDK8 and preparation method and application thereof | 合肥大学 | 2024-09-10 | — | — | CN | claimed |
| CN-118619924-A | PROTAC compound for targeted degradation of CDK8 and preparation method and application thereof | 合肥大学 | 2024-09-10 | — | — | CN | disclosed |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220054488-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2022-02-24 | — | — | US | disclosed |
| CN-112279848-A | Pan-JAKs inhibitor and application thereof | 四川海思科制药有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-11-07 | — | — | US | disclosed |
| WO-2018106870-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054488-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | HSD17B10 2660/4885PLA2G10 3361/4885PLA2G5 2898/4885 |
| US-20190336503-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | CDK4, CDK6, CDK2 | HSD17B10 2660/4885PLA2G10 3361/4885PLA2G5 2898/4885 |
| US-11541051-B2 | Compositions and methods for treating CDK4/6-mediated cancer | CDK4, CDK6, CDK2 | HSD17B10 2660/4885PLA2G10 3361/4885PLA2G5 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.